trial

Cognitive Effects of Nimodipine in Patients With Schizophrenia

NCTId NCT03671525
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Early Phase 1 · Completed
Enrollment 18 (actual)
Sponsored by Johns Hopkins University
Primary completion 2023-05-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Early Phase 1
Status
Completed
Enrollment
18 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2018-10-05
Primary completion
2023-05-12
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Nimodipine

Sponsors

Johns Hopkins UniversityLead Sponsor

Investigators

1
Kristin Bigos, PhDPrincipal Investigator

Sites

2 total
Baltimore, United StatesBaltimore, United States

Facts & assertions

4 sourced
Enrollment
18
Phase
EARLY_PHASE1
Primary Completion Date
2023-05-12
Status
COMPLETED
relationships
The graph out of here
drug
Nimodipine
drug
lead_sponsor
Johns Hopkins University
company
indication
Schizophrenia
indication
Schizo Affective Disorder
indication
Schizophrenia
indication
investigator
Kristin Bigos, PhD
person